JP2019513010A - プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 - Google Patents

プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 Download PDF

Info

Publication number
JP2019513010A
JP2019513010A JP2018546415A JP2018546415A JP2019513010A JP 2019513010 A JP2019513010 A JP 2019513010A JP 2018546415 A JP2018546415 A JP 2018546415A JP 2018546415 A JP2018546415 A JP 2018546415A JP 2019513010 A JP2019513010 A JP 2019513010A
Authority
JP
Japan
Prior art keywords
muscle
pge2
cells
compound
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018546415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513010A5 (enExample
Inventor
ヘレン エム． ブラウ
ヘレン エム． ブラウ
アンドリュー トリ ヴァン ホ
アンドリュー トリ ヴァン ホ
アデライダ アール． パラ
アデライダ アール． パラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019513010A publication Critical patent/JP2019513010A/ja
Publication of JP2019513010A5 publication Critical patent/JP2019513010A5/ja
Priority to JP2022089405A priority Critical patent/JP2022116259A/ja
Priority to JP2024098418A priority patent/JP2024116386A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0661—Smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
JP2018546415A 2016-03-04 2017-03-03 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 Withdrawn JP2019513010A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022089405A JP2022116259A (ja) 2016-03-04 2022-06-01 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
JP2024098418A JP2024116386A (ja) 2016-03-04 2024-06-19 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662303979P 2016-03-04 2016-03-04
US62/303,979 2016-03-04
US201662348116P 2016-06-09 2016-06-09
US62/348,116 2016-06-09
PCT/US2017/020650 WO2017152044A1 (en) 2016-03-04 2017-03-03 Compositions and methods for muscle regeneration using prostaglandin e2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022089405A Division JP2022116259A (ja) 2016-03-04 2022-06-01 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2019513010A true JP2019513010A (ja) 2019-05-23
JP2019513010A5 JP2019513010A5 (enExample) 2020-04-09

Family

ID=59743257

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546415A Withdrawn JP2019513010A (ja) 2016-03-04 2017-03-03 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
JP2022089405A Pending JP2022116259A (ja) 2016-03-04 2022-06-01 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
JP2024098418A Pending JP2024116386A (ja) 2016-03-04 2024-06-19 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022089405A Pending JP2022116259A (ja) 2016-03-04 2022-06-01 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
JP2024098418A Pending JP2024116386A (ja) 2016-03-04 2024-06-19 プロスタグランジンｅ２を用いる、筋再生のための組成物および方法

Country Status (10)

Country Link
US (2) US20240415849A1 (enExample)
EP (2) EP4538365A3 (enExample)
JP (3) JP2019513010A (enExample)
KR (2) KR102387896B1 (enExample)
CN (2) CN109072186B (enExample)
AU (3) AU2017225999B2 (enExample)
CA (1) CA3014667A1 (enExample)
DK (1) DK3423067T3 (enExample)
ES (1) ES3039622T3 (enExample)
WO (1) WO2017152044A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024177548A (ja) * 2016-09-26 2024-12-19 アルコン インコーポレイティド 熱により調整可能な眼内レンズ

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN110891568A (zh) 2017-04-07 2020-03-17 凯斯西储大学 用于治疗冠状动脉病症的短链脱氢酶活性的抑制剂
AU2018280264B2 (en) 2017-06-09 2024-07-11 Myoforte Therapeutics, Inc. Compositions and methods for preventing or treating muscle conditions
PE20212246A1 (es) 2018-11-21 2021-11-24 Univ Case Western Reserve Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta
JP2022530232A (ja) * 2019-04-30 2022-06-28 パエアン バイオテクノロジー インコーポレイテッド 活性成分として単離されたミトコンドリアを含む、筋炎を予防又は治療するための医薬組成物
KR20220019760A (ko) * 2019-06-11 2022-02-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 15-하이드록시프로스타글란딘 데하이드로게나제(15-pgdh)를 억제하여 노화된 조직을 젊어지게 하는 방법
JP2022547620A (ja) * 2019-09-16 2022-11-14 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ 組織再生のための方法及び組成物
US20230210829A1 (en) * 2020-06-11 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Rejuvenation of aged tissues by inhibition of the pge2 degrading enzyme, 15-pgdh
US20240000758A1 (en) * 2020-10-23 2024-01-04 The Board Of Trustees Of The Leland Stanford Junior University Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331389A1 (en) * 2012-06-11 2013-12-12 National Cheng Kung University Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells
WO2015065716A1 (en) * 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927213A (en) * 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5833978A (en) * 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
EP1132086B1 (en) 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
SK5562003A3 (en) * 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
EP1417975B1 (en) 2001-07-23 2011-03-02 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US6841573B2 (en) * 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20080234337A1 (en) * 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
PE20071230A1 (es) 2006-02-09 2008-01-16 Schering Corp Combinaciones y metodos de inhibidores del vhc
RU2425876C2 (ru) * 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EA200970067A1 (ru) 2006-07-28 2009-08-28 Пфайзер Продактс Инк. Агонисты ep2
CA2706879A1 (en) 2007-11-29 2009-06-11 Robert M. Burk Substituted cyclopentanes having prostaglandin activity
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
EP2272948A4 (en) 2008-04-11 2012-08-08 Univ Keio METHOD OF INSULATING A SMOOTH MUSCLE STEM CELL
EP2637702A4 (en) * 2010-11-11 2014-11-26 Univ Miami METHODS, COMPOSITIONS, CELLS AND KITS FOR TREATING ISCHEMIC INJURIES
EP2785350B1 (en) * 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
EP3295940A1 (en) * 2012-04-16 2018-03-21 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331389A1 (en) * 2012-06-11 2013-12-12 National Cheng Kung University Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells
WO2015065716A1 (en) * 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024177548A (ja) * 2016-09-26 2024-12-19 アルコン インコーポレイティド 熱により調整可能な眼内レンズ

Also Published As

Publication number Publication date
EP3423067B1 (en) 2025-07-23
JP2024116386A (ja) 2024-08-27
EP3423067A1 (en) 2019-01-09
CN109072186A (zh) 2018-12-21
BR112018017228A2 (pt) 2019-02-05
DK3423067T3 (da) 2025-09-15
KR102387896B1 (ko) 2022-04-15
KR102481354B1 (ko) 2022-12-23
US20250090549A1 (en) 2025-03-20
WO2017152044A1 (en) 2017-09-08
KR20220049615A (ko) 2022-04-21
CA3014667A1 (en) 2017-09-08
AU2022268368A1 (en) 2022-12-15
AU2022268368B2 (en) 2024-09-19
EP3423067A4 (en) 2019-09-04
AU2024278535A1 (en) 2025-01-16
CN116716241A (zh) 2023-09-08
US20240415849A1 (en) 2024-12-19
EP4538365A2 (en) 2025-04-16
AU2017225999B2 (en) 2022-08-18
EP4538365A3 (en) 2025-07-30
CN109072186B (zh) 2023-06-23
AU2017225999A1 (en) 2018-08-30
JP2022116259A (ja) 2022-08-09
KR20180129804A (ko) 2018-12-05
ES3039622T3 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
AU2022268368B2 (en) Compositions and methods for muscle regeneration using prostaglandin E2
US11969433B2 (en) Compositions and methods for muscle regeneration using prostaglandin E2
US11738031B2 (en) Compositions and methods for preventing or treating muscle conditions
Arthur et al. The effect of physiological stimuli on sarcopenia; impact of Notch and Wnt signaling on impaired aged skeletal muscle repair
WO2016025629A1 (en) Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
AU2012308097A1 (en) Treatment of bone diseases
JP2020500197A (ja) 骨格筋肥大誘発剤としてのｌｓｄ１阻害剤
HK40001925A (en) Compositions and methods for muscle regeneration using prostaglandin e2
HK40001925B (en) Compositions and methods for muscle regeneration using prostaglandin e2
BR112018017228B1 (pt) Composição compreendendo inibidor da 15- hidroxiprostaglandina desidrogenase (15-pgdh), e seu uso
BR122025016540A2 (pt) Composição compreendendo um pge2, um derivado de pge2, um análogo de pge2, um pró-fármaco de pge2 ou um agonista do receptor ep4 de prostaglandina, e seu uso
ES2903411T3 (es) AMD3100 para el tratamiento y/o la prevención de caquexia, y composición farmacéutica del mismo
Yuan et al. α-ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1-dependent adrenal activation
JP2024020797A (ja) 筋萎縮の治療剤
WO2025085598A2 (en) Personalized regenerative cells
van Erp Modifying function and fibrosis of cardiac and skeletal muscle from mdx mice
JPWO2013038740A1 (ja) 筋肥大を促進する物質又は因子のスクリーニング方法
WO2007123010A1 (ja) 骨代謝改善剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181106

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220202

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220601

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220613

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240625